ARWR Arrowhead Pharmaceuticals, Inc.
ARWR Arrowhead Pharmaceuticals, Inc.
Healthcare · Biotechnology
Desk view
Market read
POC $64.89 · VWAP $67.30 · -13.8% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster Director + 1 other sold $1.2M, Aug 20
Coverage
1 watchlist
ARWR Price Structure
Loading timeframes…
Peers
Every watchlist ARWR belongs to, members best 30-day change first — ARWR highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported the quarter ending 2026-06-30: revenue $75M, diluted EPS -$1.36, net income -$194M (SEC filing). Across the print the stock moved +0.9% (close before → first close after).
full note →Against street estimates
How ARWR's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. A consensus out of line with the name's earlier estimates (opposite sign to all of them and over 3x their size) is not graded. EPS only.
Recent news
Headlines about ARWR from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 8 days ago · Oct 15
- Investors | Arrowhead Pharmaceuticals Inc.
- Arrowhead Pharmaceuticals Q3 2026 Earnings Results and Report
- Arrowhead Pharmaceuticals Corp. (ARWR) Stock Price Today - The Wall Street Journal
- Arrowhead Pharmaceuticals Reports Fiscal 2026 Second Quarter Results
- Arrowhead Pharmaceuticals Reports 2025 Fiscal Year-End Results
ARWR research tape
45 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.